Here are three things to know.
1. The proposed budget includes $2 billion in fees for the FDA to collect from the drug and device industry, which is almost double the allotted amount in the 2017 budget, according to the report.
2. The Trump administration said industries that benefit from FDA approvals “can and should pay for their share,” amid such a constrained budget environment, reports Reuters. In return, the administration vowed to implement measures to speed up approvals, although specific examples were not included in the budget.
3. The FDA has charged companies for regulatory review since 1992. Most of the fees the agency collects come from reviewing new drugs. The agency brought in an estimated $866 million for reviewing new brand name drugs and about $324 million for reviewing generic drugs in 2017, according to the report.
More articles on supply chain:
Patients often skip, delay or ration cancer treatments due to high drug costs: 5 takeaways
7 things to know about Dr. Scott Gottlieb’s relationship with the drug industry
Mylan settles biosimilar patent dispute with Roche: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.